340 related articles for article (PubMed ID: 22242557)
1. Danusertib, an aurora kinase inhibitor.
Meulenbeld HJ; Mathijssen RH; Verweij J; de Wit R; de Jonge MJ
Expert Opin Investig Drugs; 2012 Mar; 21(3):383-93. PubMed ID: 22242557
[TBL] [Abstract][Full Text] [Related]
2. Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
Gontarewicz A; Brümmendorf TH
Recent Results Cancer Res; 2010; 184():199-214. PubMed ID: 20072840
[TBL] [Abstract][Full Text] [Related]
3. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.
Steeghs N; Eskens FA; Gelderblom H; Verweij J; Nortier JW; Ouwerkerk J; van Noort C; Mariani M; Spinelli R; Carpinelli P; Laffranchi B; de Jonge MJ
J Clin Oncol; 2009 Oct; 27(30):5094-101. PubMed ID: 19770380
[TBL] [Abstract][Full Text] [Related]
4. Aurora kinase inhibitors as anti-cancer therapy.
Lok W; Klein RQ; Saif MW
Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
[TBL] [Abstract][Full Text] [Related]
5. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
6. ENMD-2076 for hematological malignancies.
How J; Yee K
Expert Opin Investig Drugs; 2012 May; 21(5):717-32. PubMed ID: 22397360
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.
Bosotti R; Carpinelli P; Healy S; Locatelli G; Cappella P; Lanfrancone L; Calogero R; Moll J; Isacchi A
Gene; 2012 Feb; 494(2):202-8. PubMed ID: 21914463
[TBL] [Abstract][Full Text] [Related]
8. Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.
Steeghs N; Mathijssen RH; Wessels JA; de Graan AJ; van der Straaten T; Mariani M; Laffranchi B; Comis S; de Jonge MJ; Gelderblom H; Guchelaar HJ
Invest New Drugs; 2011 Oct; 29(5):953-62. PubMed ID: 20182906
[TBL] [Abstract][Full Text] [Related]
9. Aurora kinases: new targets for cancer therapy.
Carvajal RD; Tse A; Schwartz GK
Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
[TBL] [Abstract][Full Text] [Related]
10. Is there a future for Aurora kinase inhibitors for anticancer therapy?
Carpinelli P; Moll J
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
[TBL] [Abstract][Full Text] [Related]
11. Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.
Fraedrich K; Schrader J; Ittrich H; Keller G; Gontarewicz A; Matzat V; Kromminga A; Pace A; Moll J; Bläker M; Lohse AW; Hörsch D; Brümmendorf TH; Benten D
Clin Cancer Res; 2012 Sep; 18(17):4621-32. PubMed ID: 22753592
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinases as anticancer drug targets.
Gautschi O; Heighway J; Mack PC; Purnell PR; Lara PN; Gandara DR
Clin Cancer Res; 2008 Mar; 14(6):1639-48. PubMed ID: 18347165
[TBL] [Abstract][Full Text] [Related]
13. Aurora kinase inhibitors.
Kitzen JJ; de Jonge MJ; Verweij J
Crit Rev Oncol Hematol; 2010 Feb; 73(2):99-110. PubMed ID: 19369091
[TBL] [Abstract][Full Text] [Related]
14. AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer.
Kimura S
Curr Opin Investig Drugs; 2010 Dec; 11(12):1442-9. PubMed ID: 21154126
[TBL] [Abstract][Full Text] [Related]
15. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10).
Cheung CH; Coumar MS; Chang JY; Hsieh HP
Expert Opin Ther Pat; 2011 Jun; 21(6):857-84. PubMed ID: 21591849
[TBL] [Abstract][Full Text] [Related]
16. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
Cheung CH; Sarvagalla S; Lee JY; Huang YC; Coumar MS
Expert Opin Ther Pat; 2014 Sep; 24(9):1021-38. PubMed ID: 24965505
[TBL] [Abstract][Full Text] [Related]
17. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
18. Aurora kinases as targets for cancer therapy.
Mountzios G; Terpos E; Dimopoulos MA
Cancer Treat Rev; 2008 Apr; 34(2):175-82. PubMed ID: 18023292
[TBL] [Abstract][Full Text] [Related]
19. Aurora kinase inhibitors as anticancer molecules.
Katayama H; Sen S
Biochim Biophys Acta; 2010; 1799(10-12):829-39. PubMed ID: 20863917
[TBL] [Abstract][Full Text] [Related]
20. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
Cohen RB; Jones SF; Aggarwal C; von Mehren M; Cheng J; Spigel DR; Greco FA; Mariani M; Rocchetti M; Ceruti R; Comis S; Laffranchi B; Moll J; Burris HA
Clin Cancer Res; 2009 Nov; 15(21):6694-701. PubMed ID: 19825950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
